Yubai Zhou

Yubai Zhou

Auto-generated profile, based on publicly available information

Yubai Zhou

Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YZYubai Zhou
Yubai Zhou
SMSandip Mukherjee
Sandip Mukherjee
DHDaowei Huang
Daowei Huang
MCMolee Chakraborty
Molee Chakraborty
CGChunfang Gu
Chunfang Gu
XWXiaodong Wang
Xiaodong Wang

25 July 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
YZYubai Zhou
Yubai Zhou
PCPratima Chapagain
Pratima Chapagain
DDDesmarini Desmarini
Desmarini Desmarini
DUDilipkumar Uredi
Dilipkumar Uredi
MSMichael A. Stashko
Michael A. Stashko
XWXiaodong Wang
Xiaodong Wang
The kinase activity of human inositol phosphate multikinase (IPMK) is required for the synthesis of higher-order inositol phosphate signaling molecules, regulation of gene expression, and control of the cell cycle. Here, we report a novel series of highly potent IPMK inhibitors. The first-generation IPMK inhibitor 1 (UNC7437) decreased cellular proliferation and tritiated inositol phosphate levels in metabolically labeled human U251-MG glioblastoma cells. It also impacted the transcriptome of these cells, selectively regulating 993 genes enriched in cancer, epithelial-to-mesenchymal transition (EMT), and inflammatory and viral infection pathways, consistent with anticancer growth activity. Extensive optimization of 1 led to 14 (UNC9750) with improved pharmacokinetic properties. Compound 14 inhibited cellular accumulation of InsP5, the direct product of IPMK kinase activity, while having no effect on either InsP6 or InsP7 levels. These studies suggest that rapid chemical inhibition of IPMK induces a novel InsP5 metabolic signature, providing new biological insights into inositol phosphate metabolism and signaling.

11 April 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DKDeyu Kong
Deyu Kong
JZJichen Zhao
Jichen Zhao
DHDaowei Huang
Daowei Huang
MSMichael A. Stashko
Michael A. Stashko
DYDan Yan
Dan Yan
XWXiaodong Wang
Xiaodong Wang

22 February 2022 in Molecules
Verified
Journal Article
Open access
PDF file
LWLi Wang
Li Wang
YZYubai Zhou
Yubai Zhou
XWXuedan Wu
Xuedan Wu
XMXinrui Ma
Xinrui Ma
BLBing Li
Bing Li
ZLZibo Li
Zibo Li
MerTK (Mer tyrosine kinase), a receptor tyrosine kinase, is ectopically or aberrantly expressed in numerous human hematologic and solid malignancies. Although a variety of MerTK targeting therapies are being developed to enhance outcomes for patients with various cancers, the sensitivity of tumors to MerTK suppression may not be uniform due to the heterogeneity of solid tumors and different tumor stages. In this report, we develop a series of radiolabeled agents as potential MerTK PET (positron emission tomography) agents. In our initial in vivo evaluation, [18F]-MerTK-6 showed prominent uptake rate (4.79 ± 0.24%ID/g) in B16F10 tumor-bearing mice. The tumor to muscle ratio reached 1.86 and 3.09 at 0.5 and 2 h post-injection, respectively. In summary, [18F]-MerTK-6 is a promising PET agent for MerTK imaging and is worth further evaluation in future studies.